### Innovation at Work

**Florida**

<table>
<thead>
<tr>
<th>Total Direct and Indirect Economic Output of the Biopharmaceutical Sector</th>
<th>$33.7 billion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Employment Supported by the Biopharmaceutical Sector</td>
<td>155,309</td>
</tr>
</tbody>
</table>

![Image: University of Florida (UF), Gainesville, FL](image1)

#### Local Perspective: Stuart, FL

"As caregiver for my husband, I personally experienced the tragedy of losing him to Alzheimer's disease. Because there is no prevention, effective treatment or cure, it is imperative that Congress allocate funds for research to end this horrific disease."

Doris Sanders, Alzheimer’s Association advocate

<table>
<thead>
<tr>
<th>Floridians 65 and older with Alzheimer’s disease in 2016</th>
<th>510,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total NIH Award Funding (FY17)</td>
<td>$654 million</td>
</tr>
</tbody>
</table>

A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.

#### Research in the Sunshine State

**University of Florida (UF), Gainesville, FL**

Researchers have discovered that cells infected by a specific virus will become resistant to future infections by the same or closely related viruses. National Science Foundation (NSF)-funded researchers at UF are working to better understand and harness this function to prevent infections.

**Teva Pharmaceutical Industries, Tampa, FL**

Huntington’s disease (HD) is a degenerative and ultimately fatal genetic disorder. Teva Pharmaceutical is conducting phase II clinical trials testing the safety and efficacy of a new treatment for HD.

**Mayo Clinic Florida, Jacksonville, FL**

Researchers at the Mayo Clinic are testing whether “extracellular” RNA in blood can serve as a biomarker for liver disease and cancer. This clinical trial could lead to the development of new diagnostics for these diseases, as well as a tool to predict the likelihood of response to treatment or recurrence of cancer after surgery.

---

**Sources:** National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America (PhRMA), Centers for Disease Control and Prevention (CDC), A ResearchAmerica Survey of U.S. Adults Conducted in Partnership with Zogby Analytics in January 2017, National Science Foundation (NSF), Alzheimer’s Association, ClinicalTrials.gov.